Economic and humanistic burden of fibromyalgia in the USA
Expert Review of Pharmacoeconomics and Outcomes Research, ISSN: 1473-7167, Vol: 6, Issue: 3, Page: 303-314
2006
- 8Citations
- 49Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations8
- Citation Indexes8
- CrossRef5
- Captures49
- Readers49
- 49
Review Description
Fibromyalgia is a complex, chronic condition involving persistent and widespread pain of unknown origin. In the USA the syndrome affects approximately 2% of the population, with prevalence increasing with age, and has a greater predominance in females. The results of this review have found that there is a considerable economic burden associated with this disease, and in particular, the effect of the syndrome on economic losses associated with work activities is at least as important as direct medical costs. The humanistic burden is more difficult to quantify due to the numerous symptoms associated with this disease: widespread pain, persistent fatigue, feeling of weakness, sleep disturbances, morning stiffness, bowel and bladder irritability, mood disturbances, cognitive difficulties, dyesthesia/parethesia, chronic rhinitis, palpitations, auditory/vestibular/ocular complaints, regional pain and joint swelling. Overall, additional research is needed to quantify the impact of fibromyalgia on sufferers in the USA and the cost-effectiveness of alternative treatment strategies. © 2006 Future Drugs Ltd.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know